Claudio Javier SalomÃ³n

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7946954/publications.pdf

Version: 2024-02-01

61 papers	1,364 citations	279487 23 h-index	360668 35 g-index
64 all docs	64 docs citations	64 times ranked	1632 citing authors

#	Article	IF	Citations
1	Design and optimization of pH-sensitive Eudragit nanoparticles for improved oral delivery of triclabendazole. International Journal of Pharmaceutics, 2022, 617, 121594.	2.6	10
2	The Effect of Different Formulations of Praziquantel in Reducing Worms in the Prepatent Period of Schistosomiasis in Murine Models. Frontiers in Public Health, 2022, 10, .	1.3	1
3	Improving the oral delivery of benznidazole nanoparticles by optimizing the formulation parameters through a design of experiment and optimization strategy. Colloids and Surfaces B: Biointerfaces, 2022, 217, 112678.	2.5	7
4	A quality by design approach for optimization of Lecithin/SpanÂ® 80 based nanoemulsions loaded with hydrophobic drugs. Journal of Molecular Liquids, 2021, 321, 114743.	2.3	11
5	Elucidating the Splitting Behavior of Tablets to Optimize the Pharmacotherapy in Veterinary Medicine. AAPS PharmSciTech, 2021, 22, 67.	1.5	1
6	Surfactant-Free Glibenclamide Nanoparticles: Formulation, Characterization and Evaluation of Interactions with Biological Barriers. Pharmaceutical Research, 2021, 38, 1081-1092.	1.7	7
7	In vitro studies and preclinical evaluation of benznidazole microparticles in the acute Trypanosoma cruzi murine model. Parasitology, 2021, 148, 566-575.	0.7	9
8	Improving the Dissolution of Triclabendazole from Stable Crystalline Solid Dispersions Formulated for Oral Delivery. AAPS PharmSciTech, 2020, 21, 16.	1.5	14
9	A Novel Prototype Device for Microencapsulation of Benznidazole: In Vitro/In Vivo Studies. AAPS PharmSciTech, 2020, 21, 112.	1.5	2
10	Nanodelivery of nitazoxanide: impact on the metabolism of Taenia crassiceps cysticerci intracranially inoculated in mice. Therapeutic Delivery, 2020, 11, 329-339.	1.2	8
11	Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review. Acta Tropica, 2019, 198, 105080.	0.9	28
12	Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?. Colloids and Surfaces B: Biointerfaces, 2019, 177, 169-177.	2.5	31
13	Structural Elucidation of Poloxamer 237 and Poloxamer 237/Praziquantel Solid Dispersions: Impact of Poly(Vinylpyrrolidone) over Drug Recrystallization and Dissolution. AAPS PharmSciTech, 2018, 19, 1274-1286.	1.5	2
14	Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations. PLoS ONE, 2018, 13, e0207625.	1.1	34
15	Solving the Delivery Problems of Triclabendazole Using Cyclodextrins. AAPS PharmSciTech, 2018, 19, 2311-2321.	1.5	16
16	In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensionsâ€"a metabolic approach. Drug Delivery and Translational Research, 2018, 8, 1265-1273.	3.0	11
17	Development and Evaluation of Buccal Films Based on Chitosan for the Potential Treatment of Oral Candidiasis. AAPS PharmSciTech, 2017, 18, 936-946.	1.5	59
18	Stealth nanocarriers based sterosomes using PEG post-insertion process. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 31-38.	2.0	11

#	Article	IF	Citations
19	Formulation and in-vitro efficacy of antifungal mucoadhesive polymeric matrices for the delivery of miconazole nitrate. Materials Science and Engineering C, 2017, 79, 140-150.	3.8	45
20	Recent Trends in the Development of Chitosan-Based Drug Delivery Systems. AAPS PharmSciTech, 2017, 18, 933-935.	1.5	26
21	Development andÂin vitro/in vivoÂevaluation of a novel benznidazole liquid dosage form using a qualityâ€byâ€design approach. Tropical Medicine and International Health, 2017, 22, 1514-1522.	1.0	14
22	Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease. PLoS Neglected Tropical Diseases, 2017, 11, e0006119.	1.3	28
23	Unexpected solvent impact in the crystallinity of praziquantel / poly(vinylpyrrolidone) formulations. A solubility, DSC and solid-state NMR study. International Journal of Pharmaceutics, 2016, 511, 983-993.	2.6	29
24	Elucidating the influence of praziquantel nanosuspensions on the in vivo metabolism of Taenia crassiceps cysticerci. Acta Tropica, 2016, 161, 100-105.	0.9	20
25	Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies. American Journal of Tropical Medicine and Hygiene, 2016, 95, 388-393.	0.6	37
26	First solid-state NMR spectroscopy evaluation of complexes of benznidazole with cyclodextrin derivatives. Carbohydrate Polymers, 2015, 131, 90-97.	5.1	19
27	Elucidating the guest-host interactions and complex formation of praziquantel and cyclodextrin derivatives by 13 C and 15 N solid-state NMR spectroscopy. International Journal of Pharmaceutics, 2015, 496, 812-821.	2.6	18
28	13C and 15N solid-state NMR studies on albendazole and cyclodextrin albendazole complexes. Carbohydrate Polymers, 2015, 123, 130-135.	5.1	24
29	Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. Journal of Antimicrobial Chemotherapy, 2015, 70, 2945-2955.	1.3	68
30	Chitosan microparticles: influence of the gelation process on the release profile and oral bioavailability of albendazole, a class II compound. Drug Development and Industrial Pharmacy, 2014, 40, 1476-1482.	0.9	11
31	Design, Characterization, and In Vitro Evaluation of Antifungal Polymeric Films. AAPS PharmSciTech, 2013, 14, 64-73.	1.5	15
32	Effects of benznidazole:cyclodextrin complexes on the drug bioavailability upon oral administration to rats. International Journal of Biological Macromolecules, 2013, 62, 543-548.	3.6	50
33	Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi. Parasitology International, 2013, 62, 79-81.	0.6	10
34	Unexpected Performance of Physical Mixtures over Solid Dispersions on the Dissolution Behavior of Benznidazole from Tablets. Journal of Pharmaceutical Sciences, 2013, 102, 1016-1023.	1.6	17
35	First Century of Chagas' Disease: An Overview on Novel Approaches to Nifurtimox and Benznidazole Delivery Systems. Journal of Pharmaceutical Sciences, 2012, 101, 888-894.	1.6	67
36	The 1st International Meeting on Pharmaceutical Sciences (1er RICiFa). AAPS PharmSciTech, 2010, 11, 1-1.	1.5	10

#	Article	IF	Citations
37	Preparation, characterization and dissolution studies of fast release diclofenac sodium tablets from PVP solid dispersions. Pharmaceutical Development and Technology, 2010, 15, 162-168.	1.1	7
38	Influence of water uptake, gel network, and disintegration time on prednisone release from encapsulated solid dispersions. Pharmaceutical Development and Technology, 2010, 15, 184-191.	1.1	3
39	In vivo evaluation of albendazole microspheres for the treatment of Toxocara canis larva migrans. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 451-454.	2.0	39
40	Development of novel formulations for Chagasâ€™ disease: Optimization of benznidazole chitosan microparticles based on artificial neural networks. International Journal of Pharmaceutics, 2009, 367, 140-147.	2.6	65
41	High efficacy of albendazole-PEG 6000 in the treatment of Toxocara canis larva migrans infection. Journal of Antimicrobial Chemotherapy, 2009, 64, 375-378.	1.3	13
42	Influence of water uptake, gel network, and disintegration time on prednisone release from encapsulated solid dispersions. Pharmaceutical Development and Technology, 2009, 00, 090721052554029-8.	1.1	0
43	Preparation, characterization and dissolution studies of fast release diclofenac sodium tablets from PVP solid dispersions. Pharmaceutical Development and Technology, 2009, 00, 090710041713042-7.	1.1	3
44	Development of prednisone: Polyethylene glycol 6000 fast-release tablets from solid dispersions: Solid-state characterization, dissolution behavior, and formulation parameters. AAPS PharmSciTech, 2007, 8, E108.	1.5	54
45	Development of parenteral formulations and evaluation of the biological activity of the trypanocide drug benznidazole. International Journal of Pharmaceutics, 2006, 307, 239-243.	2.6	50
46	Macromolecules Applied to Pharmaceutical Chemistry. Molecules, 2005, 10, 3-5.	1.7	0
47	Carbamoylphosphonates, a New Class of in Vivo Active Matrix Metalloproteinase Inhibitors. 1. Alkyl- and Cycloalkylcarbamoylphosphonic Acids. Journal of Medicinal Chemistry, 2004, 47, 2826-2832.	2.9	47
48	Swellable Matrices for the Controlledâ€Release of Diclofenac Sodium: Formulation and In Vitro Studies. Pharmaceutical Development and Technology, 2004, 9, 75-83.	1.1	35
49	Foreword to the Proceedings of the 12th National Symposium of Organic Chemistry "Dr. Eduardo Guerreiro", Los Cocos (CÃ³rdoba), Argentina, 14-17 November 1999. Molecules, 2000, 5, 283-284.	1.7	0
50	Regioselective Opening of Epoxides Catalyzed by Sn (IV). A New Method for the Synthesis of Halohydrins?. Molecules, 2000, 5, 468-469.	1.7	0
51	A Practical Method for the Disposal of Organotin Residues from Reaction Mixtures. Journal of Organic Chemistry, 2000, 65, 9220-9222.	1.7	15
52	Synthesis of New Potential NMDA Antagonist Based on Acylphosphonate Derivatives. Phosphorus, Sulfur and Silicon and the Related Elements, 1999, 147, 367-367.	0.8	2
53	Recent Applications of Organotin Oxides/Hydroxides and Alkylstannonic Acids in Organic Synthesis. Phosphorus, Sulfur and Silicon and the Related Elements, 1999, 150, 89-97.	0.8	7
54	Interaction of Myosin Subfragment 1 with Two Non-Nucleotide ATP Analogues. Biochemistry, 1998, 37, 15137-15143.	1.2	3

#	Article	IF	Citations
55	REGIO- AND STEREOSELECTIVE ALCOHOLYSIS OF (R)-STYRENE OXIDE WITH BIS-TRIBUTYLTIN OXIDE AND BIS-CHLORODIBUTIYLTIN OXIDE. Main Group Metal Chemistry, 1998, 21, .	0.6	2
56	Spontaneous Lossen Rearrangement of (Phosphonoformyl)hydroxamates. The Migratory Aptitude of the Phosphonyl Group. Journal of Organic Chemistry, 1997, 62, 3858-3861.	1.7	26
57	Efficient and selective dealkylation of phosphonate dilsopropyl esters using Me3SiBr. Tetrahedron Letters, 1995, 36, 6759-6760.	0.7	16
58	Scope and Mechanism of Deprotection of Carboxylic Esters by Bis(tributyltin) Oxide. Journal of Organic Chemistry, 1994, 59, 7259-7266.	1.7	64
59	Recent developments in chemical deprotection of ester functional groups. Tetrahedron, 1993, 49, 3691-3734.	1.0	87
60	Stereospecific synthesis, 1H and 13C NMR spectroscopy, and X-ray crystallographic studies of 6,6-dibromo-3Î±-cyano-2,2-dimethylpenam-(1R)-S-oxide. Canadian Journal of Chemistry, 1991, 69, 578-583.	0.6	9
61	Bis (tributyltin) oxide. A mild, neutral and selective reagent for cleavage of esters. Scope and limitation of the reaction. Tetrahedron Letters, 1991, 32, 4239-4242.	0.7	45